| Bioactivity | Tadnersen sodium, an antisense oligonucleotide (ASO), selectively targets C9ORF72 transcript variants 1 and 3 that carry the expansion[1]. |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Smeyers J, et al. C9ORF72: What It Is, What It Does, and Why It Matters. Front Cell Neurosci. 2021;15:661447. Published 2021 May 5. [2]. Aoki Y, et al. Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases [published online ahead of print, 2021 Jun 3]. J Neuromuscul Dis. 2021;10.3233/JND-200560. |